Works matching IS 15747891 AND DT 2022 AND VI 16 AND IP 17

Results: 8

Kaiso phosphorylation at threonine 606 leads to its accumulation in the cytoplasm, reducing its transcriptional repression of the tumour suppressor CDH1.

Published in:

Molecular Oncology, 2022, v. 16, n. 17, p. 3192, doi. 10.1002/1878-0261.13292

By:

Wei Tian;
Hongfan Yuan;
Sisi Qin;
Wensu Liu;
Baozhen Zhang;
Liankun Gu;
Jing Zhou;
Dajun Deng

Publication type:

Article

Elucidating tumour-associated microglia/macrophage diversity along glioblastoma progression and under ACOD1 deficiency.

Published in:

Molecular Oncology, 2022, v. 16, n. 17, p. 3167, doi. 10.1002/1878-0261.13287

By:

Pires-Afonso, Yolanda;
Muller, Arnaud;
Grzyb, Kamil;
Oudin, Anaïs;
Yabo, Yahaya A.;
Sousa, Carole;
Scafidi, Andrea;
Poli, Aurélie;
Cosma, Antonio;
Halder, Rashi;
Coowar, Djalil;
Golebiewska, Anna;
Skupin, Alexander;
Niclou, Simone P.;
Michelucci, Alessandro

Publication type:

Article

Profiling the 3D interaction between germ cell tumors and microenvironmental cells at the transcriptome and secretome level.

Published in:

Molecular Oncology, 2022, v. 16, n. 17, p. 3107, doi. 10.1002/1878-0261.13282

By:

Skowron, Margaretha A.;
Eul, Katharina;
Stephan, Alexa;
Ludwig, Gillian F.;
Wakileh, Gamal A.;
Bister, Arthur;
S€ohngen, Christian;
Raba, Katharina;
Petzsch, Patrick;
Poschmann, Gereon;
Kuffour, Edmund Osei;
Degrandi, Daniel;
Ali, Shafaqat;
Wiek, Constanze;
Hanenberg, Helmut;
Münk, Carsten;
Stühler, Kai;
Köhrer, Karl;
Mass, Elvira;
Nettersheim, Daniel

Publication type:

Article

High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE-hypermutated colorectal cancers.

Published in:

Molecular Oncology, 2022, v. 16, n. 17, p. 3055, doi. 10.1002/1878-0261.13257

By:

Favre, Loetitia;
Cohen, Justine;
Calderaro, Julien;
Pécriaux, Adrien;
Cong-Trung Nguyen;
Bourgoin, Rémi;
Larnaudie, Laura;
Dupuy, Aurélie;
Ollier, Marie;
Lechapt, Emmanuèle;
Sloma, Ivan;
Tournigand, Christophe;
Rousseau, Benoit;
Pujals, Anaïs

Publication type:

Article

Arachidonic acid, a clinically adverse mediator in the ovarian cancer microenvironment, impairs JAK-STAT signaling in macrophages by perturbing lipid raft structures.

Published in:

Molecular Oncology, 2022, v. 16, n. 17, p. 3146, doi. 10.1002/1878-0261.13221

By:

Hammoud, Mohamad K.;
Dietze, Raimund;
Pesek, Jelena;
Finkernagel, Florian;
Unger, Annika;
Bieringer, Tim;
Nist, Andrea;
Stiewe, Thorsten;
Bhagwat, Aditya M.;
Nockher, Wolfgang Andreas;
Reinartz, Silke;
Müller-Brüsselbach, Sabine;
Graumann, Johannes;
Müller, Rolf

Publication type:

Article

Mesenchymal tumor cells drive adaptive resistance of Trp53<sup>-/-</sup> breast tumor cells to inactivated mutant Kras.

Published in:

Molecular Oncology, 2022, v. 16, n. 17, p. 3128, doi. 10.1002/1878-0261.13220

By:

van Weele, Linda J.;
Djomehri, Sabra I.;
Cai, Shang;
Antony, Jane;
Sikandar, Shaheen S.;
Qian, Dalong;
Ho, William H. D.;
West, Robert B.;
Scheeren, Ferenc A.;
Clarke, Michael F.

Publication type:

Article

USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K.

Published in:

Molecular Oncology, 2022, v. 16, n. 17, p. 3082, doi. 10.1002/1878-0261.13217

By:

Prieto-Garcia, Cristian;
Hartmann, Oliver;
Reissland, Michaela;
Braun, Fabian;
Bozkurt, Süleyman;
Pahor, Nikolett;
Fuss, Carmina;
Schirbel, Andreas;
Schülein-Völk, Christina;
Buchberger, Alexander;
Calzado Canale, Marco A.;
Rosenfeldt, Mathias;
Dikic, Ivan;
Münch, Christian;
Diefenbacher, Markus E.

Publication type:

Article

KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors.

Published in:

Molecular Oncology, 2022, v. 16, n. 17, p. 3066, doi. 10.1002/1878-0261.13213

By:

Paniagua, Guillem;
Jacob, Harrys K. C.;
Brehey, Oksana;
García-Alonso, Sara;
Lechuga, Carmen G.;
Pons, Tirso;
Musteanu, Monica;
Guerra, Carmen;
Drosten, Matthias;
Barbacid, Mariano

Publication type:

Article